Daewoong Pharmaceutical obtains approval for phase 1 clinical trials of COVID-19 drug Niclosamide

Company
R&D·Tech
Product
Investors
Sustainability
Media
Careers

Introduction
DW WAY
History
Global Network
Contact Point

R&D Overview
Research Areas
Pipeline
Open Collaboration

Biologics
Chemicals
CTD LIST

IR Highlights
Financial Info
Stock Info
IR

Sustainability Report
Compliance Program
Corporate Governance

News
Brand Resource

Company

Introduction
DW WAY
History
Global Network
Contact Point

R&D·Tech

R&D Overview
Research Areas
Pipeline
- Pipeline Roadmap
- Key Pipelines
Open Collaboration

Product

Biologics
Chemicals
CTD LIST

Investors

IR Highlights
Financial Info
Stock Info
IR

Sustainability

Sustainability Report
Compliance Program
Corporate Governance

Media

News
Brand Resource

CEO
Chang-jae Lee, Seongsoo Park
Address
Bongeunsa-ro 114-gil 12, Gangnam-gu, Seoul, Korea
Corporate Registration Number
124-86-01143

Company
Introduction
DW WAY
History
Global Network
Contact Point

R&D·Tech
R&D Overview
Research Areas
Pipeline
Open Collaboration

Product
Biologics
Chemicals
CTD LIST

Investors
IR Highlights
Financial Info
Stock Info
IR

Sustainability
Sustainability Report
Compliance Program
Corporate Governance

Media
News
Brand Resource

Careers

Privacy Policy Terms of Use

Copyright 2025 DAEWOONG PHARMACEUTICAL CO.,LTD.
All rights reserved.

Daewoong Pharmaceutical obtains approval for phase 1 clinical trials of COVID-19 drug Niclosamide